Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 16, 2026

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy
07:45

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Published on: December 30, 2025

615

Diabetic macular oedema.

Gavin S Tan1, Ning Cheung1, Rafael Simó2

  • 1Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore.

The Lancet. Diabetes & Endocrinology
|August 7, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore.

Ophthalmology and therapy·2026
Same author

Epidemiological insights into epiretinal membranes using optical coherence tomography: the Singapore Epidemiology of Eye Diseases Study-2.

The British journal of ophthalmology·2026
Same author

FRZB-induced anti-angiogenic effect via Caveolin-1-mediated TGFβ signalling.

Nature communications·2026
Same author

International consensuses and guidelines on management of proliferative diabetic retinopathy (PDR) by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI).

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2025
Same author

A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study.

BMJ open ophthalmology·2025
Same author

Corrigendum to "International consensuses and guidelines on etiology, diagnosis, treatment, and future developments of neovascular age-related macular degeneration (nAMD) by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Ocular Imaging Society (APOIS) and the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO)" [Asia-Pac J Ophthalmol, Available online 29 August 2025, 100242 (2025) DOI:10.1016/j.apjo.2025.100242].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2025
Same journal

Weight management in China: integrating mental health into routine obesity care.

The lancet. Diabetes & endocrinology·2026
Same journal

Innovation is key to transforming future obesity care.

The lancet. Diabetes & endocrinology·2026
Same journal

Out of touch medical care.

The lancet. Diabetes & endocrinology·2026
Same journal

ADA Scientific Sessions 2026: a line crossed.

The lancet. Diabetes & endocrinology·2026
Same journal

Endocrine-neuropsychological interplay underpinning maternal postpartum depression.

The lancet. Diabetes & endocrinology·2026
Same journal

Intermittent fasting to treat diabetes: time to update clinical practice guidelines.

The lancet. Diabetes & endocrinology·2026
See all related articles

Diabetic macular oedema is a leading cause of vision loss in diabetics, affecting millions globally. Research is exploring new treatments beyond anti-VEGF therapies to improve outcomes.

Area of Science:

  • Ophthalmology
  • Diabetology
  • Medical Research

Background:

  • Diabetic macular oedema (DMO) is the primary cause of diabetes-related vision loss, impacting over 20 million worldwide.
  • Risk factors include poor glycemic and blood pressure control, with underlying pathophysiology involving chronic hyperglycemia and VEGF.
  • Optical coherence tomography (OCT) enables early detection and monitoring of DMO.

Purpose of the Study:

  • To review current understanding of diabetic macular oedema.
  • To discuss established and emerging therapeutic strategies.
  • To highlight areas for future research in DMO management.

Main Methods:

  • Literature review of epidemiological studies and pathophysiological mechanisms.
  • Analysis of current and novel treatment modalities for DMO.

More Related Videos

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.7K
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.4K

Related Experiment Videos

Last Updated: Mar 16, 2026

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy
07:45

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Published on: December 30, 2025

615
Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.7K
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.4K
  • Discussion of advancements in diagnostic imaging and therapeutic targets.

    • Main Results:

    • Poor glycemic and blood pressure control are key risk factors for DMO.
    • Anti-VEGF intraocular pharmacotherapy is the current standard of care, but has limitations.
    • Emerging strategies focus on enhancing VEGF suppression, targeting inflammation, and exploring alternative pathways.

    Conclusions:

    • Diabetic macular oedema requires ongoing research for improved screening, diagnosis, and management.
    • Novel therapeutic approaches are being investigated to overcome limitations of current treatments.
    • Integrated strategies targeting multiple pathways show promise for future DMO therapy.